Drug Trial Radar · NCT07791043
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
274
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Aug 11, 2028
Study completion Jan 14, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.
Conditions
- Liver Diseases, Alcoholic
Interventions
Efimosfermin alfaDrug
Efimosfermin alfa will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM)Time frame: Baseline (Day 1) and up to Week 60
- Change from Baseline in model for end-stage liver disease (MELD) scoreTime frame: Baseline (Day 1) and up to Week 60
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Chandler, Arizona · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Topeka, Kansas · Recruiting
GSK Investigational Site
Fort Worth, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
CABA, Argentina · Recruiting
GSK Investigational Site
Ciudad AutOnoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
Rosario, Argentina · Recruiting
GSK Investigational Site
San Miguel de Tucumán, Argentina · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Athens, Greece · Recruiting
GSK Investigational Site
Athens, Greece · Recruiting
GSK Investigational Site
Daegu, South Korea · Recruiting
GSK Investigational Site
Pusan, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.